P5464 - Increasingly High Prevalence of Advanced Therapy Use in Patients With Ulcerative Colitis in a Large Community and Academic Cohort: A Preliminary Analysis From IBD Qorus

Adam A. Saleh, MD¹, Sapana Gupta, MD², Samir A. Shah, MD, FACG³, Ridhima Oberai, BS⁴, Corey A. Siegel, MD, MS⁵, Gil Y. Melmed, MD, MS, FACG⁶, Siddharth Singh, MD, MS⁷, David Fudman, MD¹
1University of Texas Southwestern Medical Center, Dallas, TX; 2Brown University / Rhode Island Hospital, Providence, RI; 3Gastroenterology Associates, Inc. powered by the GI alliance, Providence, RI; 4Crohn's and Colitis Foundation, New York, NY; 5Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; 6F. Widjaja Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center, Los Angeles, CA; 7University of California San Diego, San Diego, CA

Introduction: Underuse of advanced therapies (AT) in ulcerative colitis (UC) may contribute to suboptimal outcomes. We aimed to describe AT utilization within IBD Qorus, a large multicenter learning health system, and investigate factors associated with AT use.

Methods: Patient and provider survey responses from IBD Qorus were collected prospectively from November 2020 to May 2025 at 48 academic and community sites during routine clinical visits. We included visits with recorded current medication use and IBD classification of UC. We report descriptive statistics and a multivariable logistic regression with variable selection using the backward Wald method to identify factors associated with AT use. Differences in PRO2 between patients using versus not using AT were assessed with the Mann–Whitney U test. We additionally measured the rates of AT use in UC visits over time in 6 month intervals.

Results: Patient and provider survey responses from IBD Qorus were collected prospectively from November 2020 to May 2025 at 48 academic and community sites during routine clinical visits. We included visits with recorded current medication use and IBD classification of UC. We report descriptive statistics and a multivariable logistic regression with variable selection using the backward Wald method to identify factors associated with AT use. Differences in PRO2 between patients using versus not using AT were assessed with the Mann–Whitney U test. We additionally measured the rates of AT use in UC visits over time in 6 month intervals.

Discussion: In this large cohort encompassing both community and academic sites, AT was used in over half of all ulcerative colitis visits. To our knowledge, this prevalence exceeds that reported in other cohorts, possibly due to cohort members’ interest in IBD or participation in the IBD Qorus collaborative. Our data also reveal a trend of increasing AT use among UC patients. Future research should investigate how advanced therapy utilization evolves over time and across different clinical settings—particularly with respect to patient outcomes—to better guide and optimize the use of these treatments.


Figure: TABLE 1: Baseline characteristics of QORUS patients with Ulcerative Colitis.


Figure: Table 2. Multivariate analysis for factors associated with advanced therapy use. Variable inputs were selected by the backward Wald method. Associated odds ratios with the 95% confidence interval are given for included variables.

Disclosures:
Adam Saleh indicated no relevant financial relationships.
Sapana Gupta indicated no relevant financial relationships.
Samir Shah: pfizer – Advisory Committee/Board Member. Roche Information Systems – Consultant.
Ridhima Oberai indicated no relevant financial relationships.
Corey A. Siegel: AbbVie – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Boomerang – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Celltrion – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Johnson and Johnson – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Lilly – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Napo Pharmaceuticals – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Path Healthcare – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Pfizer – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Prometheus Labs – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Sanofi – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Takeda – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau. Trellus Health – Advisor or Review Panel Member, Consultant, Grant/Research Support, Speakers Bureau.
Gil Y. Melmed: AbbVie – Consultant. Arena – Consultant. Boehringer Ingelheim – Consultant. Bristol Myers Squibb – Consultant. Dieta – Consultant, Stock-privately held company. Ferring – Consultant. Fresenius Kalbi – Consultant. Genentech – Consultant. Gilead – Consultant. Iterative Scopes – Consultant. Janssen – Consultant. Lilly – Consultant. OptionCare – Personal Fees. Oshi Health – Consultant. Pfizer – Consultant, Grant/Research Support. Prometheus Labs – Consultant. Samsung Bioepis – Consultant. Takeda – Consultant. Techlab – Consultant. Treating inflammatory bowel disease using ultraviolet light – Intellectual Property/Patents. Treating inflammatory bowel disease with antifungal therapy – Intellectual Property/Patents. Verantos – Personal Fees. Viatris – Consultant.
Siddharth Singh indicated no relevant financial relationships.
David Fudman: Eli Lilly – Advisory Committee/Board Member. Fresenius Kabi – Consultant. Janssen – Advisory Committee/Board Member.

Adam A. Saleh, MD¹, Sapana Gupta, MD², Samir A. Shah, MD, FACG³, Ridhima Oberai, BS⁴, Corey A. Siegel, MD, MS⁵, Gil Y. Melmed, MD, MS, FACG⁶, Siddharth Singh, MD, MS⁷, David Fudman, MD¹. P5464 - Increasingly High Prevalence of Advanced Therapy Use in Patients With Ulcerative Colitis in a Large Community and Academic Cohort: A Preliminary Analysis From IBD Qorus, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.